Pharmacokinetics Services Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Type, Service Type, Therapeutic Application, and End User, and Geography

List of Tables

The pharmacokinetics services market size is projected to reach US$ 1,579.87 million by 2031 from US$ 874.96 million in 2023. The market is expected to register a CAGR of 7.6% during 2023-2031.

Market Drivers of the Pharmacokinetics Services Market

Rising Prevalence of Chronic and Infectious Diseases

The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune diseases has been a prime enabler of drug development efforts across the world. According to the World Health Organization's (WHO) 2024 data, ~422 million in the world suffer from diabetes, and these cases are mostly found in middle and low-income countries, causing approximately 1.5 million deaths every year. Pharmaceutical companies are at the forefront of developing drugs to treat various diseases. Pharmacokinetic studies are essential for understanding how these drugs behave in a patient's body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body. The absorption of a drug into systemic circulation affects the speed and concentration at which a drug may reach the site of action, e.g., plasma. Drug distribution pattern throughout the body varies based on its biochemical properties and body physiology. Metabolism involves the processing of the drug by the body into subsequent compounds. This step is instrumental in converting the drug into water-soluble substances to render them suitable for renal clearance. Metabolism is also important for the conversion of prodrugs, such as codeine, into active metabolites. Excretion of drugs from the body is mainly governed by kidneys; however, in several cases, drugs may be excreted via the lungs, skin, or gastrointestinal tract. ADME dynamics define the bioavailability of drugs in the body, and the maintenance doses of drugs are calculated based on their clearance times (desired plasma concentration divided by bioavailability). Understanding of clearance allows practitioners to calculate appropriate dosing rates.

Pharmacokinetic studies focus on optimizing drug dose regimens in study subjects to understand the efficacy and safety of a drug. These studies are essential for ensuring the safety of drugs that are developed for long-term treatments, which helps evaluate the suitability and stability of drug formulations in chronic disease management. Hence, the rising burden of chronic and infectious diseases underlines the importance of pharmacokinetic studies to develop safe and effective personalized treatments.

Opportunities in the Pharmacokinetics Services Market

The collection and handling of huge pharmacokinetic data generated during drug manufacturing are expensive, tedious, and time-consuming tasks. The labor- and cost-intensive nature of these tasks highlights the need for models such as pharmacokinetic simulation models and in vitro-in vivo pharmacokinetic correlation models (IVIVC) for the prediction of pharmacokinetic parameters. The pharmacokinetic simulation model is a tool that interprets drug kinetics in the living environment under specific conditions using computational and mathematical models. In addition, the IVIVC model are a fundamental part of the drug discovery process. Analyzing PK/PD predictions at the early stages of drug development is necessary for lead optimization strategies and also to further reduce attrition rates. There have been significant advancements in the development of new in-vitro and in-vivo strategies to improve and characterize pharmacokinetic properties. IVIVC models are being proposed as a cost-effective alternative to assess the biopharmaceutical properties that analyze the bioavailability of drugs and their application. Hence, such in-vivo and in-vitro models are anticipated to provide lucrative opportunities for the pharmacokinetics services market in the near future.

Pharmacokinetics Services Market: Segmental Overview

By drug type, the market is segmented into small molecules, large molecules, and vaccines. The small molecule segment held the largest market share in 2023.

The pharmacokinetics services market, by therapeutic application, is categorized into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

Pharmacokinetics Services Market: Geographical Overview

North America held the largest share of the market. According to a report by the Government of Canada, Health Canada receives hundreds of new clinical trial applications to test new drugs (including vaccines) or to introduce new uses of approved medicines. Pediatric patients (children and youth) in the country participate in clinical trials with their parents' permission. Health Canada protects individuals participating in clinical trials, including children and youth. According to the Canadian Clinical Trials Asset Map (CCTAM) report, ~3,500 clinical trials were registered in Canada in 2022, with cancer therapeutics being a significant area of focus, accounting for 1,300 cancer clinical trials in 2021. The pharmaceutical industry invested ~US$ 1.2 billion in clinical research in Canada, per the Innovative Medicines Canada report. Further, the Canadian Clinical Trials Network (CCTN) had over 6 million patient records maintained as of 2021. Thus, the demand for pharmacokinetic services increases with the surge in drug development and discovery projects in Canada. Thus, the rising number of clinical trials and research studies, and the increasing prevalence of infectious diseases and chronic disorders are among the factors propelling the pharmacokinetics services market growth in Canada.

Product Code: TIPRE00007438

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Pharmacokinetics Services Market Landscape

4.1 PEST Analysis

5. Pharmacokinetics Services Market - Key Market Dynamics

5.1 Pharmacokinetics Services Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Prevalence of Chronic and Infectious Diseases
- 5.2.2 Expanding Range of Application of Pharmacokinetic Studies
- 5.2.3 Outsourcing of Pharmacokinetics Services to CROs
5.3 Market Restraints
- 5.3.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
5.4 Market Opportunities
- 5.4.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
5.5 Future Trend
- 5.5.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
5.6 Impact of Drivers and Restraints:

6. Pharmacokinetics Services Market - Global Market Analysis

6.1 Pharmacokinetics Services Market Revenue (US$ Million), 2023-2031

7. Pharmacokinetics Services Market Analysis - by Drug Type

7.1 Overview
7.2 Small Molecule
- 7.2.1 Overview
- 7.2.2 Small Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Large Molecule
- 7.3.1 Overview
- 7.3.2 Large Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Vaccines
- 7.4.1 Overview
- 7.4.2 Vaccines: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Pharmacokinetics Services Market Analysis - by Service Type

8.1 Pre-Clinical ADME and Human Studies
- 8.1.1 Overview
- 8.1.2 Pre-Clinical ADME and Human Studies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 PK/PD Analysis and Reporting
- 8.2.1 Overview
- 8.2.2 PK/PD Analysis and Reporting: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Dosing Simulations
- 8.3.1 Overview
- 8.3.2 Dosing Simulations: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Risk Analysis
- 8.4.1 Overview
- 8.4.2 Risk Analysis: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Pharmacokinetics Services Market Analysis - by Therapeutic Application

9.1 Oncology
- 9.1.1 Overview
- 9.1.2 Oncology: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Infectious Diseases
- 9.2.1 Overview
- 9.2.2 Infectious Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Neurological Disorders
- 9.3.1 Overview
- 9.3.2 Neurological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Autoimmune Diseases
- 9.4.1 Overview
- 9.4.2 Autoimmune Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.5 Gynecological Disorders
- 9.5.1 Overview
- 9.5.2 Gynecological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.6 Cardiovascular Diseases
- 9.6.1 Overview
- 9.6.2 Cardiovascular Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.7 Respiratory Disorders
- 9.7.1 Overview
- 9.7.2 Respiratory Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.8 Others
- 9.8.1 Overview
- 9.8.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Pharmacokinetics Services Market Analysis - by End User

10.1 Pharmaceutical and Biotechnology Companies
- 10.1.1 Overview
- 10.1.2 Pharmaceutical and Biotechnology Companies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Contract Research Organization
- 10.2.1 Overview
- 10.2.2 Contract Research Organization: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Others
- 10.3.1 Overview
- 10.3.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11. Pharmacokinetics Services Market - Geographical Analysis

11.1 North America
- 11.1.1 North America Pharmacokinetics Services Market Overview
- 11.1.2 North America: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
  - 11.1.2.1 United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.1.1 Overview
    - 11.1.2.1.2 United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.1.3 United States: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.1.2.1.4 United States: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.1.2.1.5 United States: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.1.2.1.6 United States: Pharmacokinetics Services Market Breakdown, by End User
  - 11.1.2.2 Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.2.1 Overview
    - 11.1.2.2.2 Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.2.3 Canada: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.1.2.2.4 Canada: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.1.2.2.5 Canada: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.1.2.2.6 Canada: Pharmacokinetics Services Market Breakdown, by End User
  - 11.1.2.3 Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.3.1 Overview
    - 11.1.2.3.2 Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.3.3 Mexico: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.1.2.3.4 Mexico: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.1.2.3.5 Mexico: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.1.2.3.6 Mexico: Pharmacokinetics Services Market Breakdown, by End User
11.2 Europe
- 11.2.1 Europe Pharmacokinetics Services Market Overview
- 11.2.2 Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.3 Pharmacokinetics Services Market Breakdown by Countries
- 11.2.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
  - 11.2.4.1 Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.4.1.1 Overview
    - 11.2.4.1.2 Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.4.1.3 Germany: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.2.4.1.4 Germany: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.2.4.1.5 Germany: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.2.4.1.6 Germany: Pharmacokinetics Services Market Breakdown, by End User
  - 11.2.4.2 France: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.4.2.1 Overview
    - 11.2.4.2.2 France: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.4.2.3 France: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.2.4.2.4 France: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.2.4.2.5 France: Pharmacokinetics Services Market Breakdown, by Therapeutic Application

The market for infectious diseases segment is estimated to be worth US$ 19.24 million by 2031 and is expected to register a CAGR of 10.8% during the 2023-2031.

11.2.4.2.6 France: Pharmacokinetics Services Market Breakdown, by End User

11.2.4.3 United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.3.1 Overview
- 11.2.4.3.2 United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.3.3 United Kingdom: Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.2.4.3.4 United Kingdom: Pharmacokinetics Services Market Breakdown, by Service Type
- 11.2.4.3.5 United Kingdom: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.2.4.3.6 United Kingdom: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.4 Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.4.1 Overview
- 11.2.4.4.2 Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.4.3 Italy: Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.2.4.4.4 Italy: Pharmacokinetics Services Market Breakdown, by Service Type
- 11.2.4.4.5 Italy: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.2.4.4.6 Italy: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.5 Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.5.1 Overview
- 11.2.4.5.2 Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.5.3 Spain: Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.2.4.5.4 Spain: Pharmacokinetics Services Market Breakdown, by Service Type
- 11.2.4.5.5 Spain: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.2.4.5.6 Spain: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.6 Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.6.1 Overview
- 11.2.4.6.2 Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.6.3 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.2.4.6.4 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Service Type
- 11.2.4.6.5 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.2.4.6.6 Rest of Europe: Pharmacokinetics Services Market Breakdown, by End User

11.3 Asia Pacific
- 11.3.1 Asia Pacific Pharmacokinetics Services Market Overview
- 11.3.2 Asia Pacific: Pharmacokinetics Services Market
- 11.3.3 Asia Pacific: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
  - 11.3.3.1 China: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.1.1 Overview
    - 11.3.3.1.2 China: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.1.3 China: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.1.4 China: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.1.5 China: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.1.6 China: Pharmacokinetics Services Market Breakdown, by End User
  - 11.3.3.2 Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.2.1 Overview
    - 11.3.3.2.2 Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.2.3 Japan: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.2.4 Japan: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.2.5 Japan: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.2.6 Japan: Pharmacokinetics Services Market Breakdown, by End User
  - 11.3.3.3 India: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.3.1 Overview
    - 11.3.3.3.2 India: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.3.3 India: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.3.4 India: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.3.5 India: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.3.6 India: Pharmacokinetics Services Market Breakdown, by End User
  - 11.3.3.4 Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.4.1 Overview
    - 11.3.3.4.2 Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.4.3 Australia: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.4.4 Australia: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.4.5 Australia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.4.6 Australia: Pharmacokinetics Services Market Breakdown, by End User
  - 11.3.3.5 South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.5.1 Overview
    - 11.3.3.5.2 South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.5.3 South Korea: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.5.4 South Korea: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.5.5 South Korea: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.5.6 South Korea: Pharmacokinetics Services Market Breakdown, by End User
  - 11.3.3.6 Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.6.1 Overview
    - 11.3.3.6.2 Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.6.3 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.6.4 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.6.5 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.6.6 Rest of APAC: Pharmacokinetics Services Market Breakdown, by End User
11.4 Middle East and Africa
- 11.4.1 Middle East and Africa Pharmacokinetics Services Market Overview
- 11.4.2 Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.4.3 Pharmacokinetics Services Market Breakdown by Countries
- 11.4.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
- 11.4.5 Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
  - 11.4.5.1 Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.1.1 Overview
    - 11.4.5.1.2 Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.1.3 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.4.5.1.4 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.4.5.1.5 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.4.5.1.6 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by End User
  - 11.4.5.2 South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.2.1 Overview
    - 11.4.5.2.2 South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.2.3 South Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.4.5.2.4 South Africa: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.4.5.2.5 South Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.4.5.2.6 South Africa: Pharmacokinetics Services Market Breakdown, by End User
  - 11.4.5.3 United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.3.1 Overview
    - 11.4.5.3.2 United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.3.3 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.4.5.3.4 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.4.5.3.5 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.4.5.3.6 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by End User
  - 11.4.5.4 Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.4.1 Overview
    - 11.4.5.4.2 Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.4.3 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.4.5.4.4 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.4.5.4.5 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.4.5.4.6 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by End User
11.5 South and Central America
- 11.5.1 South and Central America Pharmacokinetics Services Market Overview
- 11.5.2 South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.5.3 Pharmacokinetics Services Market Breakdown by Countries
- 11.5.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
  - 11.5.4.1 Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.1.1 Overview
    - 11.5.4.1.2 Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.1.3 Brazil: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.5.4.1.4 Brazil: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.5.4.1.5 Brazil: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.5.4.1.6 Brazil: Pharmacokinetics Services Market Breakdown, by End User
  - 11.5.4.2 Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.2.1 Overview
    - 11.5.4.2.2 Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.2.3 Argentina: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.5.4.2.4 Argentina: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.5.4.2.5 Argentina: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.5.4.2.6 Argentina: Pharmacokinetics Services Market Breakdown, by End User
  - 11.5.4.3 Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.3.1 Overview
    - 11.5.4.3.2 Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.3.3 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.5.4.3.4 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.5.4.3.5 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.5.4.3.6 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by End User

12. Company Profile

12.1 Charles River Laboratories International Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Eurofins Scientific SE
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Evotec SE
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Certara Inc.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
12.5 Parexel International Corp
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Allucent
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 PACIFIC BIOLABS
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 SGS SA
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Shanghai Medicilon Inc.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners